FDA expands Pluvicto approval to earlier-stage metastatic prostate cancer, nearly doubling eligible patients
The FDA approved Pluvicto with androgen receptor inhibitors for earlier-stage PSMA-positive metastatic hormone-sensitive prostate cancer, expanding patient eligibility.